Pair page
Liraglutide with Retatrutide
Mechanism-tag overlap and published literature for Liraglutide and Retatrutide, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
Liraglutide unique
daily-glp-1-receptor-agonist
Shared
incretin-peptide
Retatrutide unique
triple-receptor-agonist
Quick facts
Liraglutide
RouteSubQ once daily
Half-life~13 hours
FDA statusApproved (T2D 2010, obesity 2014, peds 2019)
WADANot listed
Retatrutide
RouteSubQ, once weekly
Half-life~6 days
FDA statusInvestigational (Phase 3)
WADANot specifically named
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2022 | Liraglutide | Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022;327(2):138-150. PMID: 35015037. (Head-to-head sema vs lira.) PMID 35015037 | human trial |
| 2020 | Liraglutide | Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, Mastrandrea LD, Prabhu N, Arslanian S; NN8022-4180 Trial Investigators. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;382(22):2117-2128. PMID: 32320651. PMID 32320651 | human trial |
| 2020 | Liraglutide | Verma S, Bain SC, Honoré JB, et al. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure (LEADER substudy). J Am Coll Cardiol. 2020;75(13):1505-1517. PMID: 32164886. PMID 32164886 | human trial |
| 2017 | Liraglutide | Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(9):839-848. PMID: 28854085. PMID 28854085 | human trial |
| 2016 | Liraglutide | Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 201… PMID 27295427 | human trial |
| 2015 | Liraglutide | Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015… PMID 26132939 | human trial |
| 2015 | Liraglutide | Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, Andreasen AH, Jensen CB, DeFronzo RA; NN8022-1922 Study Group. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687-699. P… PMID 26284720 | human trial |
| 2013 | Liraglutide | Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-1451. PMID: 23812094. PMID 23812094 | human trial |
| 2009 | Liraglutide | Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616. PMID: 19853906. PMID 19853906 | human trial |
| — | Liraglutide | NICE. Liraglutide for the treatment of type 2 diabetes mellitus and weight management. UK National Institute for Health and Care Excellence guidance documents. | human study |
| 2014 | Liraglutide | FDA. Saxenda (liraglutide) prescribing information. December 2014, updated periodically. | regulatory / registry |
| 2010 | Liraglutide | FDA. Victoza (liraglutide) prescribing information. January 2010, updated periodically. | regulatory / registry |
| 2025 | Retatrutide | Rosenstock J, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025. PMID: 40609566. PMID 40609566 | human trial, Phase 2 |
| 2024 | Retatrutide | Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PMID: 38858523. PMID 38858523 | human trial, Phase 2 |
| 2023 | Retatrutide | Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. DOI: 10.1056/NEJMoa2301972. PMID 37366315 | human trial, Phase 2 |
| 2023 | Retatrutide | Rosenstock J, Frías JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544.… PMID 37385280 | human trial, Phase 2 |
| 2025 | Retatrutide | Eli Lilly and Company. Topline TRIUMPH-4 readout — retatrutide in adults with obesity and knee osteoarthritis. Press release, October 2025. | human trial |
| 2023 | Retatrutide | Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131. (Comparator reference.) PMID 37952131 | human trial |
| 2022 | Retatrutide | Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024. (Comparator reference.) PMID 35658024 | human trial |
| 2021 | Retatrutide | Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185. (Comparator reference.) PMID 33567185 | human trial |
| — | Retatrutide | Kjeldsen SAS, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. PMID: 41090431. PMID 41090431 | human trial |
| — | Retatrutide | ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Adult Participants Who Have Obesity or Are Overweight With Weight-Related Medical Problems (TRIUMPH-1). NCT05929066. | human trial |
| — | Retatrutide | ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Adult Participants With Obesity and Type 2 Diabetes (TRIUMPH-2). NCT05929079. | human trial |
| — | Retatrutide | ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight With Osteoarthritis of the Knee (TRIUMPH-4). NCT05931367. | human trial |
Related pair pages
More research context
Frequently asked
Have Liraglutide and Retatrutide been studied together?
No co-administration studies between Liraglutide and Retatrutide are catalogued on Kalios. The pair page lists only the individual published literature for each compound and any shared mechanism tags.
What mechanisms do Liraglutide and Retatrutide share?
Liraglutide and Retatrutide share these mechanism tags on their Kalios profiles: incretin-peptide. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Liraglutide and Retatrutide?
Liraglutide: Approved (T2D 2010, obesity 2014, peds 2019). Retatrutide: Investigational (Phase 3). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Liraglutide and Retatrutide?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Liraglutide profile and the Retatrutide profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026